Yoichiro Tohi

Editorial Comment to Impact of Clinicopathological and Institutional Factors on the Clinical Courses of Patients With Localized Prostate Cancer Initially Managed by Active Surveillance: An Analysis of Nationwide Real‐World Data From Japan

Onozawa et al. conducted a large-scale, multicenter observational study using the J-CaP registry to investigate the clinical trajectories and factors associated with discontinuation of active surveillance (AS) among 989 patients with localized prostate cancer (PCa) who were initially managed with AS across Japan betwee...

Darolutamide-based triplet therapy versus androgen receptor pathway inhibitor-based doublet therapy for metastatic castration-sensitive prostate cancer: a real-world analysis using the TriNetX database.

Cancer‐Control Outcomes of Japanese Vs. German Metastatic Hormone‐Sensitive Prostate Cancer Patients: A Real‐World Cross‐Country Comparison of Patients Undergoing Combination Therapies

Differences in tumor biology, ethnicities, and healthcare structures across populations may contribute to variability in oncologic outcomes. This study compared baseline characteristics and oncologic outcomes of Japanese and German metastatic hormone‐sensitive prostate cancer (mHSPC) patients.

Impact of PI-RADS During Active Surveillance for Prostate Cancer on Pathological Findings at Repeat Biopsy

At one year, a PI-RADS score ≥3 was associated with a higher risk of reclassification, whereas a score ≤2 was associated with a greater likelihood of no cancer on rebiopsy, highlighting the prognostic value of MRI in guiding active surveillance.